In the last three months, 11 analysts have published ratings on Ultragenyx Pharmaceutical RARE, offering a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 7 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 4 | 3 | 0 | 0 | 0 |
| 3M Ago | 0 | 2 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $100.18, a high estimate of $121.00, and a low estimate of $73.00. This current average has increased by 4.45% from the previous average price target of $95.91.
Diving into Analyst Ratings: An In-Depth Exploration
A clear picture of Ultragenyx Pharmaceutical's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Tiago Fauth | Wells Fargo | Raises | Overweight | $88.00 | $75.00 |
| Anupam Rama | JP Morgan | Lowers | Overweight | $102.00 | $105.00 |
| Whitney Ijem | Canaccord Genuity | Maintains | Buy | $121.00 | $121.00 |
| Whitney Ijem | Canaccord Genuity | Raises | Buy | $121.00 | $109.00 |
| Luca Issi | RBC Capital | Maintains | Outperform | $77.00 | $77.00 |
| Kristen Kluska | Cantor Fitzgerald | Maintains | Overweight | $116.00 | $116.00 |
| Ed Arce | HC Wainwright & Co. | Raises | Buy | $95.00 | $82.00 |
| Kristen Kluska | Cantor Fitzgerald | Maintains | Overweight | $116.00 | $116.00 |
| Yaron Werber | TD Cowen | Raises | Buy | $73.00 | $61.00 |
| Kristen Kluska | Cantor Fitzgerald | Maintains | Overweight | $116.00 | $116.00 |
| Luca Issi | RBC Capital | Maintains | Outperform | $77.00 | $77.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Ultragenyx Pharmaceutical. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Ultragenyx Pharmaceutical compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Ultragenyx Pharmaceutical's stock. This comparison reveals trends in analysts' expectations over time.
To gain a panoramic view of Ultragenyx Pharmaceutical's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Ultragenyx Pharmaceutical analyst ratings.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
A Deep Dive into Ultragenyx Pharmaceutical's Financials
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Ultragenyx Pharmaceutical's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 42.27%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -95.71%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Ultragenyx Pharmaceutical's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -34.27%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Ultragenyx Pharmaceutical's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -8.46%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.1.
Analyst Ratings: What Are They?
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
